EU/3/01/044: Orphan designation for the treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency

Human alpha1-proteinase inhibitor

Table of contents

Overview

On 9 July 2001, orphan designation (EU/3/01/044) was granted by the European Commission to Aventis Behring GmbH, Germany, for human alpha-1-proteinase inhibitor (respiratory use) for the treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency.

The sponsor changed name to ZLB Behring GmbH in February 2005 and subsequently to CSL Behring GmbH in April 2007.

Key facts

Active substance
Human alpha1-proteinase inhibitor
Intended use
Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency
Orphan designation status
Positive
EU designation number
EU/3/01/044
Date of designation
09/07/2001
Sponsor
CSL Behring GmbH
Emil-von-Behring-Str. 76
35041 Marburg
Germany
Tel. + 49 6421 3912
E-mail: EU-CSLBehring@cslbehring.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating